Aleta Biotherapeutics announces ALETA-001 Presentation at 63rd ASH Annual Meeting

businesswire.com/news/home/2021…

cc Cancer Research UK #lymphoma #leukemia #celltherapy

Aleta Biotherapeutics announces ALETA-001 Presentation at 63rd ASH Annual Meeting

businesswire.com/news/home/2021…

cc Cancer Research UK #lymphoma #leukemia #celltherapy

we'll discuss triple antigen targeting for solid tumor therapy - and the power of immune architecture - at #SITC21

businesswire.com/news/home/2021…

AletaBio

The Fall Conference Season starts off with the virtual CAR-TCR Summit next week. Join our President and CSO Paul Rennert as he chairs a Clinical Session on Wednesday at noon EST then jumps into the Start-Up Strategy Panel at 4pm EST! AletaBio CAR-TCR

This new paper from the AletaBio labs reveals a biparatopic anti-CLEC12A CAR T Engager protein, and introduces a dual-CAR T Engager that targets CLEC12A and CD33

mct.aacrjournals.org/content/early/…

#celltherapy #immunotherapy #AML #leukemia Molecular Cancer Therapeutics

Sending hearty congratulations to the Advent Life Sciences team on their closing of two new funds! Great investors, great friends. adventls.com/news/41-press-….

Aleta Bio will also be represented at the Oncology Cell Therapy Summit where I will join a town hall discussion on the challenges posed by Tumor Microenvironments - with Christopher Heery MD from Precision and Christina Coughlin from Rubius
events.kisacoresearch.com/octs-eu-2021/h…

Aleta Bio is Online this week at the B. Riley Oncology Investor Conference. We are in good company - a great line up of public and private companies presenting.
…or-conference.events.issuerdirect.com

We met the Cancer Research UK leadership via video this morning - amazing talent base in this charity. They described their adjustments to life after #Covid19 , they've done a good job keeping cancer research alive. Lucky to be working with them as ALETA-001 moves to the clinic.

The #SITC2020 virtual poster walks start this evening with our poster on a cell therapy carefully designed to treat Her2-positive breast and lung cancer patients relapsing with brain metastases without having to stop their biologic treatment - a huge win for patients

So, @bioaleta we understand the complexity of CAR T cell engineering. A new paper gave us a lot to think about, reviewed here:

sugarconebiotech.com/?page_id=37

Aleta Biotherapeutics news: Come hear our #ASH19 talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them.

businesswire.com/news/home/2019… #celltherapy #immunotherapy

Aleta Biotherapeutics news: Come hear our #ASH19 talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them.

businesswire.com/news/home/2019…
aletabio.com

Aleta Biotherapeutics news: Come hear our talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them.

#ASH19 aletabio.com
businesswire.com/news/home/2019…

Aleta Biotherapeutics news: Come hear our talk on a novel therapeutic to counter relapses in ALL & NHL patients treated with CD19 CAR-T cells. Half of these patients relapse in under a year, our goal is to rescue them.

#ASH19 aletabio.com
businesswire.com/news/home/2019…

An important and timely AletaBio update:

businesswire.com/news/home/2019…

Great news from the Aleta headquarters in Natick MA AletaBio Paul D. Rennert

businesswire.com/news/home/2019…

Aleta Bio seeking a science/medical writer/program manager to help us drive our cell therapy programs into the clinic

part time/semi-remote/metro-west Boston

and you get to work with Paul D. Rennert !!! how cool is that...

Aleta Biotherapeutics' will present preclinical date at #SITC18 showing robust tumor cytotoxicity across diverse IMPACT cell therapy programs. Aleta develops multi-antigen targeting solutions for Her2+ solid tumors, AML and B cell malignancies: poster #11102 by @pdrennert et al

Updated webpage and news from Aleta Biotherapeutics aletabio.com

AletaBio Paul D. Rennert